Taysha Gene Therapies’ (TSHA) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report issued on Tuesday morning, Benzinga reports. Chardan Capital currently has a $7.00 target price on the stock.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an overweight rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, May 28th. Canaccord Genuity Group restated a buy rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Jefferies Financial Group reaffirmed a buy rating and issued a $8.00 price objective (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Piper Sandler started coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an overweight rating and a $9.00 price target for the company. Finally, JMP Securities reaffirmed a market outperform rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus price target of $7.00.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $2.97 on Tuesday. The firm’s 50 day moving average price is $3.00 and its 200-day moving average price is $2.38. Taysha Gene Therapies has a twelve month low of $0.50 and a twelve month high of $4.32. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $555.45 million, a PE ratio of -6.06 and a beta of 0.49.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The company had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. During the same quarter last year, the business earned ($0.28) EPS. Equities research analysts expect that Taysha Gene Therapies will post -0.43 EPS for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently made changes to their positions in TSHA. FMR LLC lifted its position in shares of Taysha Gene Therapies by 2,035.0% during the 3rd quarter. FMR LLC now owns 24,527,801 shares of the company’s stock valued at $77,508,000 after buying an additional 23,378,974 shares in the last quarter. RA Capital Management L.P. purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $58,373,000. RTW Investments LP purchased a new position in shares of Taysha Gene Therapies during the 3rd quarter worth $53,382,000. Avoro Capital Advisors LLC increased its position in shares of Taysha Gene Therapies by 328.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after purchasing an additional 14,294,445 shares during the last quarter. Finally, Acuta Capital Partners LLC acquired a new position in Taysha Gene Therapies in the 3rd quarter valued at about $12,096,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.